TOP > 外国特許検索 > BIOMARKER FOR ALZHEIMER’S DISEASE

BIOMARKER FOR ALZHEIMER’S DISEASE NEW

外国特許コード F190009757
整理番号 (S2017-0642-N0)
掲載日 2019年5月7日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2018JP018849
国際公開番号 WO 2018221212
国際出願日 平成30年5月16日(2018.5.16)
国際公開日 平成30年12月6日(2018.12.6)
優先権データ
  • 特願2017-108766 (2017.5.31) JP
発明の名称 (英語) BIOMARKER FOR ALZHEIMER’S DISEASE NEW
発明の概要(英語) The present invention addresses the problem of providing a marker and an application thereof useful for early diagnosis or differentiation of Alzheimer’s disease. Provided is a biomarker for Alzheimer’s disease, comprising a blood-borne flotillin.
従来技術、競合技術の概要(英語) BACKGROUND ART
Consisting of the senile plaques in the brain to the deposition of amyloid beta protein, Alzheimer's disease (hereinafter, abbreviated as' AD ' may be) of the pathological observations and the most representative, or the deposition of amyloid formation of the polymer to cause the onset of AD are considered. Amyloid beta (A β) metabolism is therefore (production, polymer formation, as well as decomposition, removing) the adjustment of the prevention of a disease, is considered to be the target of treatment, therapeutic drug development has been performed. According to a recent study, 20 years or more before the onset of AD A β aggregates form of senile plaques were deposited at the beginning, at the onset of a brain plaques is already present in a range becomes clear. (Tau) then the tau protein aggregates the neurofibrillary tangles as a main component and will appear, mild cognitive impairment (Mild Cognitive Impairments; MCI) via a developing dementia is considered. Receives such results of studies, the National Institute on Aging (NIA; Alzheimer's disease Society National Institute on Aging) diagnostic criteria and a revised version of the year 2011, or not brain pathology condition change step of the 'before the onset of Alzheimer's disease (Preclinical AD) ' proposed (Non-Patent Document 1) have been invented. In addition, such as amyloid vaccine therapy treatment is the root to the target, after the onset of the effect to be limited to the invention will become apparent, senile plaques is already completed after the onset of amyloid pathology progresses than be treated prior to the onset is considered to be in. Under such a background, using PET image inspection or cerebrospinal fluid such as amyloid imaging method, the AD and mild cognitive impairment (MCI) prior to the onset of treatment and diagnostic stage is attempted and made an attempt, the stage of the possible in the art. However, with invasive examination of the cerebrospinal fluid, generally in the office or hospital is difficult. In addition, the device may be expensive and reagent PET, in addition to the possibility of radiation damage cannot be denied. From such a background, a more simple inexpensive small and minimally invasive diagnostic method has been expected development. On the other hand, other dementia Alzheimer's dementia is, Lewy body dementia, vascular dementia, frontotemporal dementia (FTD) type and the like, suitable for the prevention/treatment is necessary for the differential diagnosis. In fact, such as a depression in the elderly patient, Alzheimer's dementia often requires discrimination of the case.
On the other hand, in the brain that exosomes A β protein to present, to serve to remove the reported findings, in the development of AD role of exosomes is attracting attention. However, for the change in the level of exosomes AD was completely unknown. In this regard, studies of the inventors of the present invention group, in the cells treated with Aβ1-42, the secretion of exosomes reported phenomenon is significantly reduced (non-patent document 2).
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • PUBLIC UNIVERSITY CORPORATION NAGOYA CITY UNIVERSITY
  • NATIONAL UNIVERSITY CORPORATION OITA UNIVERSITY
  • 発明者(英語)
  • MICHIKAWA Makoto
  • AKATSU Hiroyasu
  • ABDULLAH Mohammad
  • MATSUBARA Etsuro
  • KIMURA Noriyuki
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、問合せボタンを押してください。

PAGE TOP

close
close
close
close
close
close